Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMR), and connected persons, specifically regarding increases in their ordinary shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
The material change reported is the increase in share ownership by specific directors and PDMRs following the re-investment of dividends paid on April 10, 2014. Shares were purchased at a price of 1,551.71 pence per share on April 11, 2014.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a regulatory disclosure of insider share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: April 11, 2014.
- Share Price: 1,551.71 pence per share.
- Transaction Type: Re-investment of dividends paid on April 10, 2014.
- Key Participants: Includes Sir Andrew Witty (1,544.981 shares), Mr S A Hussain (1,959.639 shares), and Dr P J T Vallance (988.774 shares), among others.
- Connected Persons: Mrs K Thomson acquired 34.262 shares as a connected person to Mr P C Thomson.